The course of dyskinesia induction by different treatment schedules of Levodopa in Parkinsonian rats: Is continuous dopaminergic stimulation necessary?

Movement Disorders

Volumn 23, Issue 7, 2008, Pages 950-957

  Tsironis, Christos ^a   Marselos, Marios ^a   Evangelou, Angelos ^a   Konitsiotis, Spiridon ^a  

^a UNIVERSITY OF IOANNINA   (Greece)

Author keywords

Abnormal involuntary movements; Basal ganglia; Continuous dopaminergic stimulation; Motor response complications; Parkinson's disease; Priming

Indexed keywords

BENSERAZIDE PLUS LEVODOPA; DOPAMINE RECEPTOR STIMULATING AGENT; LEVODOPA;

ABNORMAL INVOLUNTARY MOVEMENTS SCORE; ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DISEASE SEVERITY; DOPAMINERGIC SYSTEM; DOSAGE SCHEDULE COMPARISON; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG INTERMITTENT THERAPY; DRUG MEGADOSE; DYSKINESIA; LOW DRUG DOSE; MALE; MOTOR PERFORMANCE; NONHUMAN; PARKINSONISM; PHARMACOLOGICAL STIMULATION; PRIORITY JOURNAL; RAT; SCORING SYSTEM; ANIMAL; BASAL GANGLION; DRUG ADMINISTRATION; PARKINSON DISEASE; PATHOLOGY; WISTAR RAT;

ANIMALS; BASAL GANGLIA; DOPAMINE AGONISTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DYSKINESIA, DRUG-INDUCED; LEVODOPA; PARKINSON DISEASE; RATS; RATS, WISTAR;

EID: 49249093685     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.21630     Document Type: Article

References (19)

1. Lang AE, Lozano AM. Parkinson's disease. N Engl J Med 1998; 339:1130-1143.
2. Peppe A, Dambrosia JM, Chase TN. Risk factors for motor response complications in L-dopa-treated parkinsonian patients. Adv Neurol 1993;60:698-702.
3. Chase TN, Konitsiotis S, Oh JD. Striatal molecular mechanisms and motor dysfunction in Parkinson's disease. Adv Neurol 2001; 86:355-360.
4. Chase TN. Levodopa therapy: consequences of the nonphysiologic replacement of dopamine. Neurology 1998;50:17-25.
5. Stocchi F, Olanow CW. Continuous dopaminergic stimulation in early and advanced Parkinson's disease. Neurology 2004;62:S56-S63.
6. Stocchi F, Vacca L, Ruggieri S, Olanow CW. Intermittent vs continuous levodopa administration in patients with advanced Parkinson disease: a clinical and pharmacokinetic study. Arch Neurol 2005;62:905-910.
7. Rascol O, Brooks DJ, Korczyn AD, De Deyn PP, Clarke CE, Lang AE. A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. (056 Study Group). N Engl J Med 2000;342:1484-1491.
8. Schrag A, Quinn N. Dyskinesias and motor fluctuations in Parkinson's disease. A community-based study. Brain 2000;123:2297-2305.
9. Paxinos G, Watson C. The rat brain in stereotaxic coordinates, 5th ed. New York: Elsevier; 2005.
10. Schallert T, Fleming SM, Leasure JL, Tillerson JL, Bland ST. CNS plasticity and assessment of forelimb sensorimotor outcome in unilateral rat models of stroke, cortical ablation, parkinsonism and spinal cord injury. Neuropharmacology 2000;39:777-787.
11. Lee CS, Cenci MA, Schulzer M, Bjorklund A. Embryonic ventral mesencephalic grafts improve levodopa - induced dyskinesia in a rat model of Parkinson's disease. Brain 2000;123:1365-1379.
12. Carta AR, Pinna A, Morelli M. How reliable is the behavioural evaluation of dyskinesia in animal models of Parkinson's disease? Behav Pharmacol 2006;17:393-402.
13. Konitsiotis S, Tsironis C. Levodopa-induced dyskinesia and rotational behavior in hemiparkinsonian rats: independent features or components of the same phenomenon? Behav Brain Res 2006; 170:337-341.
14. Chase TN. The significance of continuous dopaminergic stimulation in the treatment of Parkinson's disease. Drugs 1998; 55:1-9.
15. Smith LA, Jackson MJ, Al-Barghouthy G, et al. Multiple small doses of levodopa plus entacapone produce continuous dopaminergic stimulation and reduce dyskinesia induction in MPTP-treated drug-naive primates. Mov Disord 2005;20:306-314.
16. Arabia G, Zappia M, Bosco D, et al. Body weight, levodopa pharmacokinetics and dyskinesia in Parkinson's disease. Neurol Sci 2002;23:S53-S54.
17. Rajput AH, Fenton ME, Birdi S, et al. Clinical-pathological study of levodopa complications. Mov Disord 2002;17:289-296.
18. Blanchet PJ. Rationale for use of dopamine agonists in Parkinson's disease: review of ergot derivatives. Can J Neurol Sci 1999;26:S21-S26.
19. Nutt JG. Continuous dopaminergic stimulation: is it the answer to the motor complications of Levodopa? Mov Disord 2007; 22:1-9.